Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
MONTREAL, Jan. 12, 2015 /PRNewswire/ – Milestone Pharmaceuticals, Inc. announced today that it received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 study of MSP-2017 for the treatment of acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT). The trial is expected to begin patient enrollment in early 2015.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.